Trials / Recruiting

RecruitingNCT06442475

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Low Dose Mosunetuzumab for Indolent B-Cell Lymphoma

Status: Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 20 (estimated)

Sponsor: University of Washington · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

Detailed description

OUTLINE: Patients receive mosunetuzumab intravenously (IV) over 2-4 hours on days 1, 8, 15 and 22. Patients also undergo blood sample collection and positron emission tomography (PET)/computed tomography (CT) on study. Patients may undergo CT and/or magnetic resonance imaging (MRI) as clinically indicated and may undergo collection of oral and/or rectal swabs on study. After completion of study treatment, patients are followed up at week 13, at 6 months, and then for up to 5 years per institutional standards.

Conditions

Interventions

Type	Name	Description
PROCEDURE	Biospecimen Collection	Undergo blood, oral, and/or rectal sample collection
PROCEDURE	Computed Tomography	Undergo PET/CT or CT
PROCEDURE	Magnetic Resonance Imaging	Undergo MRI
BIOLOGICAL	Mosunetuzumab	Given IV
PROCEDURE	Positron Emission Tomography	Undergo PET/CT
OTHER	Questionnaire Administration	Ancillary studies

Timeline

Start date: 2024-08-29
Primary completion: 2026-08-12
Completion: 2027-02-12
First posted: 2024-06-04
Last updated: 2026-03-13

Locations

1 site across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT06442475. Inclusion in this directory is not an endorsement.